Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer

被引：0
|
作者：
不详
机构：
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [1] Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
    Cunningham, David
    Chau, Ian
    Stocken, Deborah D.
    Valle, Juan W.
    Smith, David
    Steward, William
    Harper, Peter G.
    Dunn, Janet
    Tudur-Smith, Catrin
    West, Julia
    Falk, Stephen
    Crellin, Adrian
    Adab, Fawzi
    Thompson, Joyce
    Leonard, Pauline
    Ostrowski, Joe
    Eatock, Martin
    Scheithauer, Werner
    Herrmann, Richard
    Neoptolemos, John P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5513 - 5518
  • [2] Randomised trial comparing gemcitabine plus vinorelbine (Gem/Vin), gemcitabine plus cisplatin (Gem/Cis), and gemcitabine plus capecitabine (Gem/Cap) in pretreated metastatic breast cancer (MBC)
    Freier, W.
    Stemmler, H. J.
    Tessen, H.
    Gitsch, G.
    Jonat, W.
    Brugger, W.
    Kettner, E.
    Tesch, H.
    Abenhardt, W.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] GEMCITABINE (GEM) PLUS CELECOXIB IN ADVANCED PANCREATIC CANCER: A PHASE II STUDY
    Valcamonico, F.
    Ferrari, V. D.
    Simoncini, E.
    Amoroso, V.
    Vassalli, L.
    Rangoni, G.
    Grisanti, S.
    Marpicati, P.
    Marini, G.
    ANNALS OF ONCOLOGY, 2004, 15 : 70 - 70
  • [4] Adjuvant gemcitabine (GEM) versus gemcitabine plus capecitabine (GEMCAP) in resected pancreatic adenocarcinoma: A retrospective analysis
    Kang, Sora
    Yoo, Changhoon
    Lee, So Heun
    Chang, Heung-Moon
    Jeong, Jae Ho
    Kim, Kyu-Pyo
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [5] A multicenter randomized phase II study of UFT/leucovorin and radiotherapy (RT) with or without cetuximab following induction gemcitabine plus capecitabine (GEM-CAP) in locally advanced pancreatic cancer (LAPC)
    Chong, I. Y.
    Okines, A. F.
    Tait, D. M.
    Hawkins, M.
    Cunningham, D.
    Saffery, C.
    Thomas, K.
    Chau, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Efficacy of alternating-week fixed dose rate gemcitabine (FDR gem) plus capecitabine (CAP) in advanced pancreatic cancer (APC).
    Johns, Claire
    Diaz, Celso L.
    Kerridge, William
    Hwang, Jimmy
    Ko, Andrew H.
    Ternpero, Margaret A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Randomised trial of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx)in advanced pancreatic cancer.
    Heinemann, V
    Golf, A
    Seipelt, G
    Bauer, J
    Höhler, T
    Clemens, M
    Löhr, JM
    Stauch, M
    Lordick, F
    Hinke, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 340S - 340S
  • [8] Randomized comparison of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer
    Heinemann, V.
    Hoehler, T.
    Seipelt, G.
    Wein, A.
    Golf, A.
    Mahlberg, R.
    Schmid, B.
    Boeck, S.
    Neugebauer, S.
    Hochhaus, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 209 - 209
  • [9] A multicenter randomized phase II trial on Kanglaite Injection (KLT) plus gemcitabine hydrochloride (GEM) versus GEM in patients with local advanced and metastatic pancreatic cancer
    Sun, Y.
    Li, Y.
    Qin, S.
    Ma, D.
    Jiao, S. C.
    Yu, S. Y.
    Li, J.
    Liu, D.
    Song, D.
    Li, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Phase I trial of capecitabine (CAP) and gemcitabine (GEM) with concurrent radical radiotherapy in locally advanced pancreatic cancer (PAC): Initial results
    Michael, Michael
    Leong, Trevor
    Price, Timothy J.
    Ganju, Vinod
    Strickland, Andrew
    Jefford, Michael
    Muller, Anna
    Ngan, Sam
    Milner, Alvin
    Zalcberg, John R.
    ANNALS OF ONCOLOGY, 2006, 17 : 311 - 311
12345